Enterome Selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program
30 oct. 2023 06h00 HE
|
Enterome
LLS TAP is a strategic funding initiative to accelerate innovative blood cancer therapeutics Strategic equity investment of €3 million to support clinical advancement of EO2463 in Non-Hodgkin’s...
Enterome to Present Clinical Progress on its OncoMimics™ Pipeline at Upcoming Investor Meetings
25 oct. 2023 08h33 HE
|
Enterome
PARIS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on...
Enterome Presents Positive Data from Phase 1/2 SPENCER Trial of EO2401 in Adrenal Tumors at ESMO 2023 Congress
23 oct. 2023 08h00 HE
|
Enterome
Updated results demonstrate sustained efficacy with a good safety profile Degree of tumor shrinkage on CT scans correlates with strength of CD8+ T cell specific immune response against EO2401...
Enterome to Present Data on EO2401 in Adrenal Tumors at the European Society for Medical Oncology (ESMO) 2023 Congress
16 oct. 2023 06h00 HE
|
Enterome
PARIS, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...
Enterome announces first patient dosed in Phase 2 trial with OncoMimics™ immunotherapy EO2040 in Colorectal Cancer with ctDNA-defined Minimal Residual Disease
11 juil. 2023 06h00 HE
|
Enterome
First clinical trial of an OncoMimics™ immunotherapy to use liquid biopsy monitoring to measure ctDNA clearance as an indicator of treatment efficacy EO2040 is Enterome’s fourth OncoMimics™...
Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer
30 juin 2023 06h00 HE
|
Enterome
EO4010 uniquely mimics five distinct tumor-associated antigens designed to provide multi-targeted, broad tumor coverage, maximizing tumor killing and preventing immune escape Paris, France – June 30,...
Enterome's new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma
14 juin 2023 06h00 HE
|
Enterome
EO2463 uniquely targets four distinct B cell markers to maximize tumor killing and prevent immune escape, generating fast, strong and durable CD8+ T cell activation against malignant B cells ...
Enterome announces sustained positive clinical outcomes with EO2401, its lead OncoMimics™ immunotherapy, in combination therapy in Glioblastoma at ASCO
31 mai 2023 06h00 HE
|
Enterome
Updated clinical data highlight promising efficacy and sustained CD8+ T cell expansion Early data from final cohort could provide validation of the EO2401 + nivolumab + bevacizumab combination...
Enterome forms Scientific Advisory Board and Medical Advisory Group as it advances its OncoMimics™ immunotherapy pipeline for solid and liquid tumors
09 mai 2023 06h00 HE
|
Enterome
SAB and MAG comprise global key opinion leaders in translational tumor immunology and immunotherapy Paris, France – May 9, 2023 Enterome, a clinical-stage company developing first-in-class...
Enterome's Management to Attend Upcoming Meetings
10 mars 2023 07h00 HE
|
Enterome
Paris, France – March 10, 2023 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform, today...